{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:13:47Z","timestamp":1768508027158,"version":"3.49.0"},"posted":{"date-parts":[[2023,9,26]]},"group-title":"Pharmacology and Toxicology","reference-count":51,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor prescribed for the treatment and prevention of human immunodeficiency virus infection, and the treatment of chronic hepatitis B virus infection. Here, we demonstrate that creatine kinase brain-type (CKB) can form tenofovir-diphosphate (TFV-DP), the pharmacologically active metabolite, in vitro, and identify nine missense mutations (C74S, R96P, S128R, R132H, R172P, R236Q, C283S, R292Q, and H296R) that diminish this activity. Additional characterization of these mutations reveal that five (R96P, R132H, R236Q, C283S, and R292Q) have ATP dephosphorylation catalytic efficiencies less than 20% of wild-type (WT), and seven (C74S, R96P, R132H, R172P, R236Q, C283S, and H296P) induce thermal instabilities. To determine the extent CKB contributes to TFV activation in vivo, we generated a CKB knockout mouse strain,\n                  <jats:italic>\n                    Ckb\n                    <jats:sup>tm1Nnb<\/jats:sup>\n                  <\/jats:italic>\n                  . Using an in vitro assay, we show that brain lysates of\n                  <jats:italic>\n                    Ckb\n                    <jats:sup>tm1Nnb<\/jats:sup>\n                  <\/jats:italic>\n                  male and female mice form 70.5% and 77.4% less TFV-DP than wild-type brain lysates of the same sex, respectively. Additionally, we observe that\n                  <jats:italic>\n                    Ckb\n                    <jats:sup>tm1Nnb<\/jats:sup>\n                  <\/jats:italic>\n                  male mice treated with tenofovir disoproxil fumarate for 14 days exhibit a 22.8% reduction in TFV activation in liver compared to wild-type male mice. Lastly, we utilize mass spectrometry-based proteomics to elucidate the impact of the knockout on the abundance of nucleotide and small molecule kinases in the brain and liver, adding to our understanding of how loss of CKB may be impacting tenofovir activation in these tissues. Together, our data suggest that disruptions in CKB may lower levels of active drug in brain and liver.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>ABSTRACT GRAPHIC<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"559370v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.1101\/2023.09.25.559370","type":"posted-content","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:30:15Z","timestamp":1695749415000},"source":"Crossref","is-referenced-by-count":0,"title":["Tenofovir Activation is Diminished in the Brain and Liver of Creatine Kinase Brain-Type Knockout Mice"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-7313","authenticated-orcid":false,"given":"Colten D.","family":"Eberhard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-2191","authenticated-orcid":false,"given":"Eric P.","family":"Mosher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-3824","authenticated-orcid":false,"given":"Namandj\u00e9 N.","family":"Bumpus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-3750","authenticated-orcid":false,"given":"Benjamin C.","family":"Orsburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023092911551261000_2023.09.25.559370v1.1","unstructured":"Viread (tenofovir disoproxil fumarate) [packet insert]. Foster City, CA: Gilead Sciences, Inc; 2021."},{"key":"2023092911551261000_2023.09.25.559370v1.2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00138-06"},{"key":"2023092911551261000_2023.09.25.559370v1.3","unstructured":"Truvada (emtricitabine\/tenofovir disoproxil fumarate) [package insert]; Foster City, CA; Gilead Sciences, Inc; 2022."},{"key":"2023092911551261000_2023.09.25.559370v1.4","unstructured":"Descovy (emtricitabine\/tenofovir alafenamide) [package insert]; Foster City, CA; Gilead Sciences, Inc; 2022."},{"key":"2023092911551261000_2023.09.25.559370v1.5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00968-06"},{"key":"2023092911551261000_2023.09.25.559370v1.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-15"},{"key":"2023092911551261000_2023.09.25.559370v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt532"},{"key":"2023092911551261000_2023.09.25.559370v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"2023092911551261000_2023.09.25.559370v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"issue":"151","key":"2023092911551261000_2023.09.25.559370v1.10","first-page":"151r","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","year":"2012","journal-title":"Sci Transl Med"},{"key":"2023092911551261000_2023.09.25.559370v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61127-7"},{"key":"2023092911551261000_2023.09.25.559370v1.12","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000172"},{"key":"2023092911551261000_2023.09.25.559370v1.13","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2012.0089"},{"issue":"7","key":"2023092911551261000_2023.09.25.559370v1.14","doi-asserted-by":"crossref","first-page":"e25962","DOI":"10.1002\/jia2.25962","article-title":"PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project","volume":"25","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2023092911551261000_2023.09.25.559370v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30132-7"},{"key":"2023092911551261000_2023.09.25.559370v1.16","doi-asserted-by":"crossref","unstructured":"Cohen SE , Sachdev D , et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018. PMC6541554.","DOI":"10.1016\/S2352-3018(18)30288-1"},{"issue":"9","key":"2023092911551261000_2023.09.25.559370v1.17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ebiom.2015.07.008","article-title":"Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner","volume":"2","year":"2015","journal-title":"EBioMedicine"},{"key":"2023092911551261000_2023.09.25.559370v1.18","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.086744"},{"key":"2023092911551261000_2023.09.25.559370v1.19","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.121.000348"},{"issue":"4","key":"2023092911551261000_2023.09.25.559370v1.20","doi-asserted-by":"crossref","first-page":"e0195764","DOI":"10.1371\/journal.pone.0195764","article-title":"Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067","volume":"13","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"2023092911551261000_2023.09.25.559370v1.21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/aid.2020.0250","article-title":"Expression, Activity, and Regulation of Phosphorylating Enzymes in Tissues and Cells Relevant to HIV-1 Sexual Transmission","volume":"38","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023092911551261000_2023.09.25.559370v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(83)91338-0"},{"key":"2023092911551261000_2023.09.25.559370v1.23","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15336"},{"key":"2023092911551261000_2023.09.25.559370v1.24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2002.02001.x"},{"key":"2023092911551261000_2023.09.25.559370v1.25","doi-asserted-by":"publisher","DOI":"10.1002\/biof.5520080310"},{"key":"2023092911551261000_2023.09.25.559370v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(97)00343-4"},{"key":"2023092911551261000_2023.09.25.559370v1.27","doi-asserted-by":"publisher","DOI":"10.1042\/bj2810021"},{"key":"2023092911551261000_2023.09.25.559370v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03221-y"},{"issue":"9","key":"2023092911551261000_2023.09.25.559370v1.29","doi-asserted-by":"crossref","first-page":"e45949","DOI":"10.1371\/journal.pone.0045949","article-title":"Effect of SNPs on creatine kinase structure and function: identifying potential molecular mechanisms for possible creatine kinase deficiency diseases","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"2023092911551261000_2023.09.25.559370v1.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.0742520.x"},{"key":"2023092911551261000_2023.09.25.559370v1.31","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23020"},{"key":"2023092911551261000_2023.09.25.559370v1.32","doi-asserted-by":"crossref","first-page":"735334","DOI":"10.3389\/fnagi.2021.735334","article-title":"Microdissected Pyramidal Cell Proteomics of Alzheimer Brain Reveals Alterations in Creatine Kinase B-Type, 14-3-3-gamma, and Heat Shock Cognate 71","volume":"13","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"2023092911551261000_2023.09.25.559370v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2013.02.006"},{"key":"2023092911551261000_2023.09.25.559370v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.018"},{"key":"2023092911551261000_2023.09.25.559370v1.35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109025200"},{"issue":"6","key":"2023092911551261000_2023.09.25.559370v1.36","first-page":"1502","article-title":"Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells","volume":"50","year":"1996","journal-title":"Mol Pharmacol"},{"issue":"29","key":"2023092911551261000_2023.09.25.559370v1.37","doi-asserted-by":"crossref","first-page":"21220","DOI":"10.1016\/S0021-9258(19)36820-6","article-title":"Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity","volume":"267","year":"1992","journal-title":"J Biol Chem"},{"key":"2023092911551261000_2023.09.25.559370v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90110-5"},{"key":"2023092911551261000_2023.09.25.559370v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4838(94)90077-9"},{"key":"2023092911551261000_2023.09.25.559370v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2008.10.039"},{"key":"2023092911551261000_2023.09.25.559370v1.41","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002628"},{"key":"2023092911551261000_2023.09.25.559370v1.42","doi-asserted-by":"publisher","DOI":"10.1080\/15257770903155899"},{"key":"2023092911551261000_2023.09.25.559370v1.43","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.122.000855"},{"issue":"10","key":"2023092911551261000_2023.09.25.559370v1.44","first-page":"1333","article-title":"Molecular characterization of the murine thymidylate kinase gene","volume":"6","year":"1995","journal-title":"Cell Growth Differ"},{"key":"2023092911551261000_2023.09.25.559370v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2012.11.007"},{"key":"2023092911551261000_2023.09.25.559370v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2014.01.014"},{"key":"2023092911551261000_2023.09.25.559370v1.47","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.1.308"},{"key":"2023092911551261000_2023.09.25.559370v1.48","doi-asserted-by":"publisher","DOI":"10.1101\/gr.176601"},{"key":"2023092911551261000_2023.09.25.559370v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth0410-248"},{"key":"2023092911551261000_2023.09.25.559370v1.50","doi-asserted-by":"crossref","unstructured":"Veselinovic M , Yang KH , et al. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. Virology. 2014;464\u2013465:253-63. PMC4484790.","DOI":"10.1016\/j.virol.2014.07.008"},{"key":"2023092911551261000_2023.09.25.559370v1.51","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac1040"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.09.25.559370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:17:03Z","timestamp":1768454223000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.09.25.559370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2023.09.25.559370","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1021\/acsptsci.3c00250","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,9,26]]},"subtype":"preprint"}}